Application of tofacitinib/Shangjie in dermatology

Tofacitinib/Shangjie(Tofacitinib), as a JAK inhibitor, was initially mainly used for immune-related diseases such asrheumatoid arthritis, psoriatic arthritis, ulcerative colitis and ankylosing spondylitis. However, as skin immunology research continues to deepen, people have gradually discovered that the JAK pathway also plays a key role in a variety of skin inflammatory diseases, which has also promoted the increasing application of tofacitinib in the field of dermatology. Especially in recent years, overseas dermatology guidelines and real-world studies have been continuously updated, making tofacitinib’s position in dermatology more clear. Although tofacitinib is not an official indication for all dermatological diseases, its use in dermatology has gradually emerged as a potential systemic treatment option.

In psoriasis, tofacitinib inhibits theJAK-STAT signaling pathway and reduces the release of inflammatory cytokines, thereby improving skin lesions, itching and joint symptoms. For psoriasis vulgaris, oral tofacitinib can systematically control the inflammatory response and achieve significant improvement in skin lesions in some patients. Compared with traditional phototherapy or topical drugs, the advantage of tofacitinib is that it can simultaneously meet the dual treatment needs of joint symptoms and skin symptoms, making it an important choice for patients with psoriatic arthritis. Some overseas studies have pointed out that tofacitinib may also bring improvement in refractory palmoplantar pustulosis, nail psoriasis and other subtypes.

In the field of atopic dermatitis,JAK inhibitors have become a new hot topic in treatment in recent years. Although tofacitinib is not officially indicated, because it acts on multiple inflammatory signaling pathways, it is particularly suitable for patients with moderate to severe recurrent skin inflammation, especially when traditional treatments (such as topical hormones, cyclosporine, or phototherapy) are ineffective. Tofacitinib can quickly reduce skin itching, inflammatory exudation and recurrence of eczema through oral administration. This efficacy feature has gradually attracted attention in overseas dermatology clinical studies and real-world data.

Reference materials:https://www.xeljanz.com/